PRCT
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.
PROCEPT BioRobotics Corporation (PRCT) is rated C+ (2.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B); its weakest is Momentum (C+).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-14 | B- (3.0) | C+ (2.6) | B (3.4) | C+ (2.5) | C+ (2.6) | C+ (2.8) |
| 2026-11-07 | B- (3.0) | C+ (2.7) | B (3.4) | C (2.3) | C+ (2.7) | C+ (2.8) |
| 2026-10-31 | B- (3.0) | C+ (2.7) | B (3.3) | C (2.3) | F (0.0) | C (2.3) |
| 2026-10-24 | B- (3.0) | C+ (2.6) | B (3.3) | C (2.3) | F (0.0) | C (2.3) |
| 2026-10-17 | B- (3.0) | C+ (2.6) | B (3.3) | C- (2.1) | F (0.0) | C (2.2) |